Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 10:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 5,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity of H1N1 Vaccine With Trivalent Inactivated Seasonal Influenza Vaccine in Adults

NCT00985673
View directory record Official record
Conditions
Influenza
Interventions
GSK2340274A, GSK2340273A, Seasonal trivalent influenza vaccine (TIV), Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
19 Years to 40 Years
Enrollment
611 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
4
States / cities
Stockbridge, Georgia • Raleigh, North Carolina • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 31, 2026, 10:52 AM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 31, 2026, 10:52 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Study of Epetraborole in Patients With Treatment-refractory MAC Lung Disease

NCT05327803
View directory record Official record
Conditions
MAC Lung Disease, Treatment Refractory MAC Lung Disease
Interventions
Epetraborole, Placebo
Drug
Lead sponsor
AN2 Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
49
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza

NCT00957996
View directory record Official record
Conditions
Seasonal Influenza, Cough, Sore Throat, Nasal Congestion, Myalgia, Headache, Fatigue
Interventions
Peramivir
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
79
States / cities
Dothan, Alabama • Mobile, Alabama • Jonesboro, Arkansas + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2015 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT06059846
View directory record Official record
Conditions
Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBP-PI-HBr, Imipenem-cilastatin, Dummy Infusion, Dummy Tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,690 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

NCT04017962
View directory record Official record
Conditions
CMV, CMV Infection, Hematopoietic Cell Transplant
Interventions
Letermovir Pill, blood draw
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
2
States / cities
Minneapolis, Minnesota • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 2 Interventional Results available

Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia

NCT03163446
View directory record Official record
Conditions
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis
Interventions
CF-301, Placebo
Biological · Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
31
States / cities
Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 31, 2026, 10:52 AM EDT
Completed No phase listed Observational

Pediatric Infectious Disease Precision Medicine Using Sequencing Evaluation of CSF

NCT03796546
View directory record Official record
Conditions
Infection, Meningitis
Interventions
Not listed
Lead sponsor
IDbyDNA, Inc.
Industry
Eligibility
0 Years to 17 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Orange, California • San Diego, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

TAKE Steps: Motivational Interviewing to Prevent STIs

NCT05215262
View directory record Official record
Conditions
Self Efficacy, HIV Prevention, STI Prevention
Interventions
Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 19 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760
View directory record Official record
Conditions
Genotype 1 Chronic Hepatitis C, Treatment Naive
Interventions
Ribavirin, Telaprevir, Pegylated interferon alfa-2a
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
37
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2014 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Protective Efficacy of a Single Dose of the Live Attenuated Tetravalent Dengue Vaccine TV005 to Protect Against Infection With rDEN3Δ30

NCT02873260
View directory record Official record
Conditions
Dengue
Interventions
TetraVax-DV-TV005, rDEN3Δ30, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Oct 31, 2026, 10:52 AM EDT
Approved For Marketing No phase listed Expanded access

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

NCT00499720
View directory record Official record
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa Airway Infection
Interventions
Aztreonam Lysine for Inhalation
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
6 Years and older
U.S. locations
64
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 53 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2011 · Synced Oct 31, 2026, 10:52 AM EDT
Recruiting Not applicable Interventional

Care for Veterans Post-COVID-19

NCT05787379
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome
Interventions
Concordant Care Training, Education Packet Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
Not listed
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 24, 2025 · Synced Oct 31, 2026, 10:52 AM EDT
Completed No phase listed Observational

Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis

NCT02165579
View directory record Official record
Conditions
Diabetes, Foot Ulcer, Osteomyelitis
Interventions
1 cohort, standard care, observational
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 1 Interventional

Acupressure to Treat Nausea and Vomiting in HIV/AIDS Patients

NCT00017823
View directory record Official record
Conditions
HIV Infections
Interventions
Acupressure
Procedure
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2010 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Equivalence of GDC-229 and Metronidazole Vaginal Gel 0.75% in the Treatment of Bacterial Vaginosis

NCT03091777
View directory record Official record
Conditions
Bacterial Vaginosis
Interventions
GDC-229, Metronidazole Vaginal Gel 0.75%, Placebo
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
18 Years and older · Female only
Enrollment
871 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 7, 2020 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Not applicable Interventional

A Comparison of the Safety and Effectiveness of Fluconazole or Clotrimazole in the Treatment of Fungal Infections of the Mouth and Throat in Patients With AIDS

NCT00002282
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
Clotrimazole, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
17
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 10:52 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Evaluation of NWRD09 for Female Participants With Persistent HPV16 Infection

NCT07536282
View directory record Official record
Conditions
Persistent HPV16 Infection
Interventions
NWRD09, Placebo
Biological
Lead sponsor
Newish Biotech (Wuxi) Co., Ltd.
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 31, 2026, 10:52 AM EDT
Completed No phase listed Observational

Benefits of Universal Glove and Gowning

NCT01318213
View directory record Official record
Conditions
MRSA, VRE
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
19,856 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 31, 2026, 10:52 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Woodsmoke Exposure, Influenza Infection, and Nasal Immunity

NCT06841913
View directory record Official record
Conditions
Smoke Exposure, Influenza
Interventions
LAIV nasal vaccine is chosen as a model viral infection, Wood smoke, Placebo for LAIV nasal vaccine is chosen as a model viral infection, Placebo for Wood Smoke (clean Air Exposure)
Biological · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Pharmacist Intervention on the Use of Zostavax in a Community Pharmacy Setting

NCT00689013
View directory record Official record
Conditions
Herpes Zoster
Interventions
Personalized letter, Flyer advertisement, Newspaper press release
Other
Lead sponsor
University of Tennessee
Other
Eligibility
60 Years and older
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
3
States / cities
Johnson City, Tennessee • Manchester, Tennessee • Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2009 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 3 Interventional

HIV Prevention Among Substance Abusing SMI

NCT00447720
View directory record Official record
Conditions
Mentally Ill Persons, Substance Abuse, HIV Infections
Interventions
PATH
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Phase 2 Interventional

A Study of Azidothymidine in HIV-Infected Children

NCT00000982
View directory record Official record
Conditions
Encephalopathies, HIV Infections
Interventions
Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Months to 12 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2011 · Synced Oct 31, 2026, 10:52 AM EDT
Completed Not applicable Interventional Results available

Prevena™ Incisional Negative Pressure Wound Therapy in Re-operative Colorectal Surgery

NCT02509260
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Prevena wound management system, Standard wound dressings
Device · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2022 · Synced Oct 31, 2026, 10:52 AM EDT